

ENLIGHTENED innovation.
Expansive therapeutic impact.
Outpacing conventional drug discovery to unlock the full potential of high value targets
Chemoproteomics is providing a new path to a universe of previously inaccessible therapeutic targets – yet drug discovery has remained inefficient, with patients waiting for new hope. Now, Jnana scientists are unlocking the full potential of chemoproteomics to uncover unique binding sites on highly validated protein targets and accelerate the discovery of new molecules that can change the course of disease.
Learn more about Jnana’s next-generation chemoproteomics drug discovery platform.
Learn more about Jnana’s next-generation chemoproteomics drug discovery platform.


Because time is of the essence
Patients today are in need of new medicines. Jnana’s RAPID platform allows us to systematically develop small molecule medicines for any target class with unmatched speed and efficiency. Together, we are advancing first- and best-in-class therapies to treat phenylketonuria (PKU) and a broad range of immune-mediated diseases and cancers.
Explore our pipeline programs and opportunities to partner.
Explore our pipeline programs and opportunities to partner.


Explore new horizons
Drug discovery is not for the faint of heart. Breakthroughs are achieved through perseverance, wisdom gained through experience, and possibility fueled by collaboration and the power of ideas.
Be part of something bigger. Find your role at Jnana.
Be part of something bigger. Find your role at Jnana.
Follow our progress
Jun 01, 2023
Jnana Therapeutics to Present at the Jefferies Healthcare Conference
May 31, 2023
Jnana Therapeutics Reports Positive Topline Results from Phase 1a Clinical Study of JNT-517, a Potential First-in-Class Oral Treatment for PKU
May 24, 2023